Cost-effectiveness analysis of escitalopram in the treatment of Major Depressive Disorder in Germany

Kulp W, Hemels M, Greiner W, von der Schulenburg J (2005)
Value in Health 8(6): A210.

Download
Es wurde kein Volltext hochgeladen. Nur Publikationsnachweis!
Kurzbeitrag Konferenz | Veröffentlicht | Englisch
Autor
; ; ;
Erscheinungsjahr
Band
8
Zeitschriftennummer
6
Seite
A210
ISSN
PUB-ID

Zitieren

Kulp W, Hemels M, Greiner W, von der Schulenburg J. Cost-effectiveness analysis of escitalopram in the treatment of Major Depressive Disorder in Germany. Value in Health. 2005;8(6):A210.
Kulp, W., Hemels, M., Greiner, W., & von der Schulenburg, J. (2005). Cost-effectiveness analysis of escitalopram in the treatment of Major Depressive Disorder in Germany. Value in Health, 8(6), A210. doi:10.1016/S1098-3015(10)67792-3
Kulp, W., Hemels, M., Greiner, W., and von der Schulenburg, J. (2005). Cost-effectiveness analysis of escitalopram in the treatment of Major Depressive Disorder in Germany. Value in Health 8, A210.
Kulp, W., et al., 2005. Cost-effectiveness analysis of escitalopram in the treatment of Major Depressive Disorder in Germany. Value in Health, 8(6), p A210.
W. Kulp, et al., “Cost-effectiveness analysis of escitalopram in the treatment of Major Depressive Disorder in Germany”, Value in Health, vol. 8, 2005, pp. A210.
Kulp, W., Hemels, M., Greiner, W., von der Schulenburg, J.: Cost-effectiveness analysis of escitalopram in the treatment of Major Depressive Disorder in Germany. Value in Health. 8, A210 (2005).
Kulp, W., Hemels, M., Greiner, Wolfgang, and von der Schulenburg, J. “Cost-effectiveness analysis of escitalopram in the treatment of Major Depressive Disorder in Germany”. Value in Health 8.6 (2005): A210.